Denmark's Novo Nordisk has launched a surprise $9 billion bid for US obesity-focused biotech firm Metsera, upending an existing takeover offer from Pfizer and potentially disrupting the pharmaceutical landscape.
In a bid to claim dominance in the weight-loss market, Novo Nordisk is putting...